Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
28 12 2021
Historique:
received: 18 05 2021
accepted: 03 08 2021
pubmed: 29 9 2021
medline: 8 1 2022
entrez: 28 9 2021
Statut: ppublish

Résumé

Rare hematologic malignancies display evidence of both myeloid and lymphoid differentiation. Here, we describe such a novel bilineal event discovered in an adult woman with B-lymphoblastic leukemia (BLL). At the time of BLL diagnosis, the patient had a normal karyotype and a bulk sequencing panel identified pathogenic variants in BCOR, EZH2, RUNX1, and U2AF1, a genotype more typical of myeloid neoplasia. Additionally, the patient was noted to have 3-year history of cytopenias, and morphologic dyspoiesis was noted on post-treatment samples, raising the possibility of an antecedent hematologic disorder. To investigate the clonal architecture of her disease, we performed targeted sequencing on fractionated samples enriched for either B-lymphoblasts or circulating granulocytes. These studies revealed a truncal founder mutation in the spliceosome gene U2AF1 in both fractions, while distinct secondary mutations were present only in B-lymphoblasts (BCOR, NRAS) or myeloid cells (ASXL1, EZH2, RUNX1). These results indicate that both processes evolved from a common U2AF1-mutated precursor, which then acquired additional mutations during a process of divergent evolution and bilineal differentiation. Our findings highlight an atypical mechanism of BLL leukemogenesis and demonstrate the potential utility of fractionated sequencing in the characterization of acute leukemia.

Identifiants

pubmed: 34581783
pii: 477048
doi: 10.1182/bloodadvances.2021005308
pmc: PMC8714722
doi:

Substances chimiques

Splicing Factor U2AF 0
U2AF1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5612-5616

Subventions

Organisme : NCI NIH HHS
ID : K12 CA120780
Pays : United States

Informations de copyright

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Oncotarget. 2016 Oct 4;7(40):65485-65503
pubmed: 27602765
Leukemia. 1995 Oct;9(10):1783-6
pubmed: 7564526
Pathobiology. 2007;74(2):115-20
pubmed: 17587882
Mod Pathol. 1998 Dec;11(12):1211-21
pubmed: 9872654
Blood Adv. 2019 Dec 23;3(24):4228-4237
pubmed: 31869410
Blood. 2016 Nov 3;128(18):2263-2266
pubmed: 27625363
Nat Commun. 2019 Jun 21;10(1):2750
pubmed: 31227714
Blood. 2017 Jun 22;129(25):3371-3378
pubmed: 28424163
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Br J Haematol. 1986 Nov;64(3):487-91
pubmed: 3539173
Blood. 2015 Nov 19;126(21):2355-61
pubmed: 26429975
Br J Haematol. 1998 Jan;100(1):123-8
pubmed: 9450800
Oncol Lett. 2018 Jun;15(6):9745-9750
pubmed: 29805685
Leuk Res. 2006 Feb;30(2):233-9
pubmed: 16046234

Auteurs

Nathan D Montgomery (ND)

Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Jonathan Galeotti (J)

Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Steven M Johnson (SM)

Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Leah Commander (L)

Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Eric T Weimer (ET)

Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Pranil K Chandra (PK)

PathGroup, Nashville, TN.

Tariq Nazir (T)

Cape Fear Valley Cancer Treatment Center, Fayetteville, NC and.

Thomas B Alexander (TB)

Division of Pediatric Oncology, Department of Pediatrics, and.

Joshua F Zeidner (JF)

Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Matthew C Foster (MC)

Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH